Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ZEGALOGUE vs ACUVAIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ZEGALOGUE (dasiglucagon) is a glucagon receptor agonist that increases blood glucose by activating hepatic glucagon receptors, stimulating glycogenolysis and gluconeogenesis.
Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes. This reduces ocular inflammation and pain.
Treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus aged 6 years and older
Reduction of ocular pain and inflammation following cataract surgery,Treatment of ocular itching associated with seasonal allergic conjunctivitis
Initial dose: 2 mg subcutaneously once daily for 2 weeks, then increase to 7 mg subcutaneously once daily. Dose may be increased to 12 mg subcutaneously once daily after 4 weeks if additional glycemic control is needed.
1 drop in the affected eye 4 times daily.
Terminal elimination half-life is 5-7 hours in healthy adults; in hepatic impairment, half-life may be prolonged up to 12 hours, requiring dose adjustment.
Terminal elimination half-life is approximately 46 minutes in the aqueous humor following ocular administration in humans.
Dasiglucagon is metabolized via proteolytic degradation into smaller peptides and amino acids; CYP enzymes are not involved.
Primarily hepatic via conjugation with glucuronic acid; minor role of cytochrome P450 enzymes. Approximately 50% is excreted as parent drug and metabolites in urine.
Primarily renal excretion of unchanged drug (approximately 70-80%) and minor hepatic metabolism with biliary/fecal elimination (10-15%).
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for <10%.
Approximately 85% bound to albumin and alpha-1-acid glycoprotein.
>99% bound to plasma proteins, primarily albumin.
0.6-0.8 L/kg, indicating moderate tissue distribution with concentrations in tissues approximately 1.5 times plasma.
Intravenous administration in animals suggests Vd ~0.15 L/kg, indicating limited distribution; clinically, it distributes into aqueous humor after topical dosing.
Oral: 40-50% (due to first-pass metabolism); Intramuscular: 90-100%.
Ocular bioavailability is dependent on formulation; systemic bioavailability after topical ocular administration is extremely low (<1%).
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m2). Not recommended for use in patients with end-stage renal disease (e GFR <15 m L/min/1.73 m2) due to lack of data.
No adjustment required. Drug is minimally systemically absorbed.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh class A). Not studied in moderate or severe hepatic impairment (Child-Pugh class B or C); use not recommended in these patients.
No adjustment required. Drug is minimally systemically absorbed.
Not indicated for pediatric patients; safety and efficacy in patients <18 years have not been established.
Safety and efficacy in pediatric patients have not been established.
No specific dose adjustment required based on age alone. However, dosing should be cautious due to potential for decreased renal function or comorbidities; monitor renal function and volume status.
No specific dosage adjustment is recommended; use same dose as younger adults.
None.
No black box warning for ophthalmic use; however, systemic NSAIDs carry risk of serious cardiovascular and gastrointestinal events. Ophthalmic use rarely associated with corneal adverse events.
Risk of serious hypersensitivity reactions including anaphylaxis,May cause nausea and vomiting,Risk of hypoglycemia if used in patients with insulinoma or glucagonoma,May increase blood pressure and heart rate
Use with caution in patients with bleeding disorders or those on anticoagulants; may prolong bleeding time. Avoid in patients with known hypersensitivities to NSAIDs or aspirin. Can cause corneal keratopathy; discontinue if corneal epithelial breakdown occurs.
Pheochromocytoma,Insulinoma,Known hypersensitivity to dasiglucagon or any excipients
Hypersensitivity to any component of the formulation. Active corneal epithelial defect. Patients with aspirin-sensitive asthma.
No specific food interactions. After recovery, administer oral carbohydrates to replenish liver glycogen and prevent recurrent hypoglycemia. Avoid alcohol as it may impair glucose recovery.
No specific food interactions; systemic absorption is minimal with ophthalmic use. Avoid concurrent use of other NSAID eye drops due to additive irritation.
Zegalogue (dasiglucagon) is a glucagon analog for severe hypoglycemia. No human pregnancy data; animal studies show no teratogenicity at exposures up to 40 times human dose. Risk cannot be excluded; use only if benefit outweighs risk. Fetal risks: potential for maternal hypoglycemia-induced fetal distress if not treated.
Acuvail (ketorolac tromethamine ophthalmic solution) is classified as FDA Pregnancy Category C. Systemic exposure after ocular administration is minimal; however, NSAIDs may cause premature closure of the ductus arteriosus and oligohydramnios in the third trimester. Use during the first and second trimesters should be limited to cases where potential benefit outweighs risk; avoid during the third trimester due to risk of fetal harm.
No data on presence in human milk; dasiglucagon is a peptide likely degraded in GI tract. M/P ratio not determined. Caution in breastfeeding; consider risk of infant exposure vs benefit of treating maternal hypoglycemia.
Ketorolac is excreted in human milk following systemic administration, but ocular doses produce negligible systemic levels. The M/P ratio is not determined for ophthalmic use. Use with caution in nursing mothers, as the clinical significance is likely low due to minimal systemic absorption.
No pharmacokinetic data in pregnancy; dosing adjustments not recommended. Use standard dose (0.6 mg) for severe hypoglycemia regardless of trimester.
No dosage adjustment is required for ophthalmic use during pregnancy, as systemic exposure is negligible. However, avoid use in third trimester due to risks. Pharmacokinetic changes in pregnancy do not significantly alter ocular delivery.
ZEGALOGUE (dasiglucagon) is a soluble glucagon analog indicated for severe hypoglycemia. It is stable in liquid form, avoiding reconstitution. Onset of action is 10-15 minutes, with blood glucose rise similar to native glucagon. Note that it can cause nausea and vomiting; if patient is unconscious, place in recovery position. Do not use if patient has pheochromocytoma, insulinoma, or known hypersensitivity. Store at room temperature.
Acuvail (ketorolac tromethamine ophthalmic solution 0.45%) is a nonsteroidal anti-inflammatory drug (NSAID) for ocular use. It is preserved with sodium chloride and not benzalkonium chloride, reducing corneal epithelial toxicity. Administer 1 drop twice daily for ocular pain and inflammation following cataract surgery. Use caution in patients with bleeding tendencies or those on anticoagulants due to risk of increased ocular bleeding. Monitor for corneal epithelial defects and keratitis, especially with prolonged use.
Use only for severe hypoglycemia when patient is unable to take carbs orally or is unconscious.,Inject into buttock, thigh, or abdomen; no need to mix or reconstitute.,After injection, call emergency services immediately.,Administer supplemental carbs (if conscious and can swallow) after blood glucose responds.,Common side effects: nausea, vomiting, headache, injection site pain.,Store at controlled room temperature (20-25°C); do not freeze.
Wash hands before each use; do not touch tip of bottle to eye or any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Contact your doctor if you experience eye pain, redness, vision changes, or if symptoms worsen.,Do not use this medication while wearing contact lenses unless directed by your doctor.,Store at room temperature, keep bottle tightly closed when not in use, and discard within 28 days of opening.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ZEGALOGUE vs ACUVAIL, answered by our medical review team.
ZEGALOGUE is a GnRH Antagonist that works by ZEGALOGUE (dasiglucagon) is a glucagon receptor agonist that increases blood glucose by activating hepatic glucagon receptors, stimulating glycogenolysis and gluconeogenesis.. ACUVAIL is a NSAID Ophthalmic that works by Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes. This reduces ocular inflammation and pain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ZEGALOGUE and ACUVAIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ZEGALOGUE is: Initial dose: 2 mg subcutaneously once daily for 2 weeks, then increase to 7 mg subcutaneously once daily. Dose may be increased to 12 mg subcutaneously once daily after 4 weeks if additional glycemic control is needed.. The standard adult dose of ACUVAIL is: 1 drop in the affected eye 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ZEGALOGUE and ACUVAIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ZEGALOGUE is classified as Category C. Zegalogue (dasiglucagon) is a glucagon analog for severe hypoglycemia. No human pregnancy data; animal studies show no teratogenicity at exposures up to 40 times human dose. Risk c. ACUVAIL is classified as Category C. Acuvail (ketorolac tromethamine ophthalmic solution) is classified as FDA Pregnancy Category C. Systemic exposure after ocular administration is minimal; however, NSAIDs may cause . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.